title: [Not Available].
abstract: Tiagabine, a second-generation anticonvulsant drug, is marketed in France since 1997. It is also prescribed outside marketing authorization in the treatment of anxiety. They are few studies allowing arguing a relation exposure efficiency or toxicity, but intra and inter individual important variations in serum concentrations are described. Hepatic insufficiency requires a dose adaptation. In patients treated with therapeutic dose, serum levels are between 20 and 100 μg/L (50-250 nmol/L) For this molecule, the level of proof of the interest of TDM was estimated in: remaining to estimate.
authors.affiliation: Laboratoire de Pharmacologie Biologique, CHU Pontchaillou, Rennes, France. Electronic address: daniele.bentue-ferrer@univ-rennes1.fr.
authors.forename: Danièle
authors.initials: D
authors.lastname: Bentué-Ferrer
authors.affiliation: Laboratoire de Pharmacologie Biologique, CHU Pontchaillou, Rennes, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Tribut
authors.affiliation: Laboratoire de Pharmacologie Biologique, CHU Pontchaillou, Rennes, France.
authors.forename: Marie-Clémence
authors.initials: MC
authors.lastname: Verdier
keywords: pharmacologique; suivi thérapeutique; therapeutic drug monitoring; tiagabine